Document Detail

The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
MedLine Citation:
PMID:  19485928     Owner:  NLM     Status:  MEDLINE    
Inflammation is an important process and an underlying mechanism involved in atherogenesis as well as the clinical manifestations following coronary artery disease (CAD). Evidence suggests that chronic heart failure (CHF) is associated with an increased inflammatory process. Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-a), interleukin-6 (IL-6), interleukin-1 (IL-1) and adhesion molecules are elevated in states of CHF and are related to long term prognosis. Statins are among the most effective compounds reducing morbidity and mortality in patients with, or at increased risk of, CAD. Efficacy and safety of statin treatment has not been validated in patients with CHF. Several studies have reported that statins could be beneficial in patients with CHF. In addition, the beneficial effects of statins have been largely attributed to their anti-inflammatory properties. However, recent randomized, double-blind, placebo-controlled trials reported that statins did not affect clinical outcomes in patients with CHF of any cause. These data support the notion that current immunomodulation approaches in heart failure are not successful. Thus, more large scale clinical trials are required to evaluate the impact of statins on immune imbalance and its restoration in patients with CHF.
Dimitris Tousoulis; Nikolaos Papageorgiou; Alexandros Briasoulis; Charalambos Antoniades; Christodoulos Stefanadis
Related Documents :
2068028 - Congestive heart failure and converting enzyme inhibition: failure of current prognosti...
15734608 - Effects of candesartan on cardiac sympathetic nerve activity in patients with congestiv...
2385738 - Good prognosis for dilated cardiomyopathy without severe heart failure or arrhythmia.
20610458 - Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm:...
24625968 - Is it necessary to assess for fat soluble vitamin deficiencies in pediatric patients wi...
22377368 - Influence of sporting activity and smoking on peripheral lymph nodes in patients with m...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  8     ISSN:  1875-6212     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-04-09     Completed Date:  2010-08-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  114-21     Citation Subset:  IM    
1st Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  pharmacology,  therapeutic use
Cell Adhesion Molecules / metabolism
Heart Failure / drug therapy*,  immunology*,  metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  pharmacology,  therapeutic use*
Immunologic Factors / adverse effects,  pharmacology,  therapeutic use*
Immunomodulation / drug effects*
Inflammation / drug therapy,  metabolism,  prevention & control
Inflammation Mediators / blood,  metabolism
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cell Adhesion Molecules; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Immunologic Factors; 0/Inflammation Mediators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic and Molecular Determinants of Atherosclerotic Plaque Instability.
Next Document:  Targeting Dyslipidemia in the Metabolic Syndrome: An Update.